SlideShare a Scribd company logo
1 of 22
Download to read offline
May, 2018
Investor Presentation
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
Safe Harbor and Other Information
This presentation contains “forward‐looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. We intend for
such forward‐looking statements to be covered by the safe harbor provisions for forward‐looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995.
Forward‐looking statements include information concerning the market shifting to Vocera, the components of our mission, our accelerating operating leverage and target operating leverage
model, and potential future products and services.
Forward‐looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates”, “targets,”
“guidance,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “prospects,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms, although
not all forward‐looking statements contain these identifying words. Forward‐looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. We cannot
guarantee that we will achieve the plans, intentions, or expectations disclosed in our forward‐looking statements, and you should not place undue reliance on our forward‐looking statements.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. We undertake no obligation, and do not intend, to update these
forward‐looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current financial quarter. For a more complete
discussion of factors that could materially affect our financial results and operations, please refer to our Quarterly Report on Form 10-Q for the period ended March 31, 2018 that we have
filed with the SEC, including Part II, Item 1A, “Risk Factors,” and other reports that we file with the SEC. Copies of reports we file with the SEC are posted on our website and are available from
us without charge.
This presentation shall not constitute an offer to sell or a solicitation of an offer to purchase securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which
or to any person to whom such an offer, solicitation or sale would be unlawful. This presentation is strictly confidential and is being made solely in reliance on applicable exemptions from the
registration requirements of the Securities Act of 1933. The securities of the Company have not been registered under the Securities Act of 1933 or any state securities laws and may not be
offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and applicable state laws. Any purchaser of
such securities will be deemed to have made certain representations and acknowledgments, including, without limitation, that the purchaser is a "qualified institutional buyer" as defined in
Rule 144A under the Securities Act of 1933.
Statement Regarding Use of Non-GAAP Financial Measures
This presentation contains certain non-GAAP financial measures. For a presentation of the most directly comparable financial measures calculated in accordance with GAAP, and a
reconciliation of these non-GAAP measures to the GAAP measures, please see the appendix.
The non-GAAP financial measures we present are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. We encourage investors to
carefully review our results of operations under GAAP in addition to the non-GAAP information we present to more fully understand our business.
2
Forward-Looking Statements
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
3
• Large market shifting toward Vocera
• Market leader with compelling ROI
• Large wins validate sales strategy
• Software acquisition extends platform
• Accelerating operating leverage
Our Opportunity
* The Company adopted ASC 606 effective January 1, 2018. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the
adoption of ASC 606 revenue in 2016 and 2017 was $127.7MM and $162.5MM, respectively; and A-EBITDA was 3% and 8% of revenue in 2016 and 2017, respectively. The adoption of ASC 606
did not impact 2014 or 2015. Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and
option liabilities. See Appendix for a reconciliation. Guidance was provided April 26, 2018.
YoY Rev.
Growth
$95
$104
$132 $166
$183*
-13%
-3%
8%
10% 11%
FY14 FY15 FY16 FY 17 FY18* Guide
High-End
Revenue A-EBITDA %
(7%) 9% 27% 26% 10%
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
Vocera Before Vocera Now
Communications
Badge-Centric
Point Product
Department Sale
Clinical Workflow
Software-Centric
Complete Solution
Enterprise Sale
Strategic Transformation
4
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
Quality ResiliencyPatient-CenteredCost
Enhance how care is
provided to help
patients to achieve
better outcomes
Increase
operational
efficiencies
Improve patient
experience by allowing
caregivers to be
Patient Centered
Improve the caregiver
experience by improving
workflow and empowering
care teams
The Quadruple Aim
5
Our Mission
©2017 Vocera Communications. All rights reserved.
6
Broadcast to OR Turnover
Call on-call Orthopedic Surgeon
Secure text to on-call Cardiologist
Urgent call to ED Charge Nurse
The Call Sheet Transformed
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
7
Communicate, Collaborate, Make Informed
Decisions Quickly
PHYSICIAN
✓ Collaborate whether inside
or outside the hospital
NURSE
✓Reach the right person
without names or numbers
NURSE SUPERVISOR
✓Keep nurses and
patients safer
HOSPITALIST
✓Receive timely, relevant
patient information
HOUSEKEEPING
✓Increase bed turnover
Alert & Alarm
Intelligence
Electronic
Health Record
Nurse Call
Physiologic
Monitor
Bed
Management
Real-Time
Location System
Laboratory
Info System
INPUTS
Dynamic Data
Aggregation of Patient
Events and Context
OUTPUTS
Context-Aware Events
Response and Critical
Collaboration
Dynamic Master
Directory
©2017 Vocera Communications. All rights reserved.
6,986
Hospitals
in the U.S.(1)
U.S. Hospitals
1118
(1)
8
Large Global Market Opportunity
(1 ) Based on Definitive US Healthcare Database. As of December 31, 2017
International
Healthcare Facilities
~250
Global Non-
Healthcare Facilities
~270
~$6 Billion Global Market Opportunity
1118
5220
Vocera Hospitals US Hospitals
18% U.S. Penetration Rate
(1)
(6338 Total US Hospitals)
*Federal numbers are for acute care hospitals, do not include clinics or ambulatory care centers
~130 new healthcare facilities in 2017
Fed Hospitals
(1)
Vocera* Total
(1)
VA 73 164
DoD 21 46
Total 94 210
U.S. Healthcare
(non hospital)
100
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
9
Recent Platform Wins Validate Strategy
MEDCOM
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
10
The Patient Journey in a Real Time Health System
Admission,
discharge,
transfer
Test
results
Nurse-
physician
consult
Obtain,
clarify, change
orders
Update
Patient
status
Streamline
Patient
flow
“The RTHS uses information
and communication technology
to reduce the time in which
patient information and
medical knowledge is collected,
analyzed, shared and applied.”
Source: Gartner Real-Time Health System Technologies, July 2017
Requirements:
• Aware
• Integrated
• Collaborative
• Patient-Centric
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
(1) Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and option liabilities. See
appendix for a reconciliation. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the company’s
adoption of ASC 606 revenue was $127.7 MM and $162.5MM in 2016 and 2017, respectively; and adjusted EBITDA was $4.3MM and $13.1MM in 2016 and 2017, respectively.
Revenue (1) Financial Highlights
Adjusted EBITDA
$36.6 $40.2
$132.0
$166.0
Q117 Q118 2016 2017
($inMillions)
-$0.6
$1.8
$10.1
$16.4
Q117 Q118 2016 2017
($inMillions)
Q1 2018 Results exceeded expectations
• Q1: 10% Revenue Growth, 2017: +26%
• Q1: 41% Software Growth, 2017: +26%
• $109.2 million Backlog + Deferred Revenue
Solid Customer Base and Value Proposition
• 95%+ s/w maintenance renewal rate
• Strong competitive win rate
Expanding Profitability and Cash Flow
• A-EBITDA $16.4 million in 2017 (1)
• A-EBITDA $1.8 million in Q118
• $82 million in cash on balance sheet
11
+10% +26%
Financial Highlights
N/MMargin (%) 4.5% 7.7% 9.9%
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
12
% 2017
Revenue
17%
Software
Maintenance
*All recurring
32%
Professional
Services
*15%+ recurring
13%
38%
Devices
*44% recurring
Diversified Revenue, High Visibility
• Greater than 50%
of revenues are
recurring
• High visibility
• Low customer
concentration
Software
*10%+ subscription
*%’s are of the specific category, not company revenue.
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
Software
Maintenance
Professional
Services
Software
Hardware
13
Larger Deals, Higher Software Mix
$9.4M $14.9M $14.4M $3.5M $3.1M
$ values are in bookings
VA = New facilities added in 2017
$1.9M
31%
18%
32% 30%
13%
34%
12%
14%
13% 19%
24%
15%
39%
29%
35%
19%
56%
51%
18%
39%
20%
32%
7%
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
14
Actual
2014 2015 2016 2017
R&D % of Revenue 17% 15% 13% 15%
S&M % of Revenue 47% 41% 35% 31%
G&A % of Revenue 13% 12% 11% 10%
Target Model
12%
29%
8%
Sales
Notes
• All numbers are non-GAAP, see appendix for reconciliation.
• Mean peer group enterprise value comps are 3-4x Revenue and 12-15x A-EBITDA.
• 2016 and 2017 reflect the company’s adoption of ASC 606. Prior to the Company’s adoption of ASC 606 the corresponding percentages would have been as follows. For 2016:
63%, 13%, 37%, 11%, 61% and 3% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively. For
2017: 64%, 16%, 32%, 10%, 58%, and 8% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively.
Drivers
Operating Leverage Drives Significant Value
Thank you!
Appendix
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
17
GAAP to Non-GAAP Reconciliations of Net Income
to Adjusted EBITDA 2014-2017
As
Adjusted
As
Reported
Change As
Adjusted
As
Reported
Change
GAAP net income (loss) (10,897) (14,217) 3,320 (11,400) (17,267) 5,867
Add back:
Stock compensation expense 18,196 18,196 - 12,035 12,035 -
Acquisition related expenses 1,269 1,269 - 5,822 5,822 -
Interest income (549) (549) - (627) (627) -
Depreciation and amortization expense 7,643 7,643 - 3,770 3,770 -
Provision for income taxes 759 759 - 529 529 -
Non-GAAP adjusted EBITDA 16,421 13,101 3,320 10,129 4,262 5,867
As Adjusted: financials recast in accordance with the Company's adoption of ASC 606.
As Reported: financials as initially reported and does not include adjustments related to the adoption of ASC 606.
Year EndedDecember 31, 2017 Year EndedDecember 31, 2016
2015 2014
GAAP net loss (17,106)$ (28,297)$
Add back:
Stock compensation expense 11,005 11,084
Acquisition expense - 899
Litigation expense 9 630
Restructuring expense - 654
Interest income (446) (267)
Depreciation and amortization expense 3,271 3,000
Provision for income taxes 473 324
Non-GAAP adjusted EBITDA (2,794)$ (11,973)$
Twelve months endedDecember 31,
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
18
GAAP to Non-GAAP Reconciliations of Net Income
to Adjusted EBITDA Q1’18 and Q1’17
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
19
GAAP to Non-GAAP GM & Opex Reconciliation
2017 & 2016 under ASC 606
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
20
GAAP to Non-GAAP GM & Opex Reconciliation
2017 & 2016 under ASC 605
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
21
GAAP to Non-GAAP Reconciliation 2015
Year ended December 31, 2015
Stock Intangible
(In thousands) GAAP compensation amortization Litigation Total Non-GAAP
2015 expense (a) (b) expense (c) adjustments 2015
Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited)
Revenue
Product $ 55,716 $ — $ 55,716
Service 48,370 — 48,370
Total revenue 104,086 — — — — 104,086
Cost of revenue
Product 19,666 232 323 555 19,111
Service 19,844 1,036 — 1,036 18,808
Total cost of
revenue 39,510 1,268 323 — 1,591 37,919
Gross profit 64,576 (1,268) (323) — (1,591) 66,167
Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited)
Research and
development 16,990 1,072 — 1,072 15,918
Sales and marketing 47,647 4,486 229 4,715 42,932
General and
administrative 16,734 4,179 243 9 4,431 12,303
Total operating
expenses 81,371 9,737 472 9 10,218 71,153
(a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense.
(b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense.
(c) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit.
©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved.
22
GAAP to Non-GAAP GM & Opex Reconciliation
2014
Year ended December 31, 2014
(In thousands)
Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited)
Revenue
Product 51,095$ $ - 51,095$
Services 44,326 - 44,326
Total Revenue 95,421 - - - - - - 95,421
Cost of Revenue
Product 18,766 254 429 72 755 18,011
Services 18,470 924 26 950 17,520
Total cost of revenue 37,236 1,178 429 - - 98 1,705 35,531
Gross profit 58,185 (1,178) (429) - - (98) (1,705) 59,890
Research and development 18,089 1,056 11 54 1,121 16,968
Sales and marketing 49,694 4,111 291 83 4,485 45,209
General and administrative 18,481 4,739 93 888 630 419 6,769 11,712
Total operating expenses 86,264 9,906 384 899 630 556 12,375 73,889
(a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense.
(b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense.
(c) This operating expense adjustment reflects the accounting impact of acquisitions, including for Q4 2014 $800K of consideration deemed to be compensation.
(d) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit.
(e) This operating expense adjustment reflects impact of restructuring expense.
Non-GAAP
2014
Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited)
GAAP
2014
Stock
compensation
expense (a)
Intangible
amortization
(b)
Acquisiton
expense (c)
Litigation
expense (d)
Restructuring
expense (e)
Total
Adjustments

More Related Content

What's hot

Vocera investordeck august 2018 web version
Vocera investordeck  august 2018 web versionVocera investordeck  august 2018 web version
Vocera investordeck august 2018 web versionvocera2016ir
 
Investor Presentation
Investor PresentationInvestor Presentation
Investor Presentationvocera2016ir
 
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017medreleafinvestor
 
Med releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 finalMed releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 finalmedreleafinvestor
 
Canni med investor presentation third qtr 2017
Canni med investor presentation   third qtr 2017Canni med investor presentation   third qtr 2017
Canni med investor presentation third qtr 2017CannimedTherapeutics
 
Hsah spin off merger slides final
Hsah spin off merger slides finalHsah spin off merger slides final
Hsah spin off merger slides finalVince Stanzione
 
1 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v201 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v20veriskir
 
Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817medreleafinvestor
 
Verisk investor day 2017
Verisk investor day 2017Verisk investor day 2017
Verisk investor day 2017veriskir
 
Investor Presentation - April 2018
Investor Presentation - April 2018Investor Presentation - April 2018
Investor Presentation - April 2018vocera2016ir
 
1500090053
15000900531500090053
1500090053veriskir
 
1001205097
10012050971001205097
1001205097veriskir
 
Akg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressedAkg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressedasanko6699
 
Verisk investor day 2017
Verisk investor day 2017Verisk investor day 2017
Verisk investor day 2017veriskir
 
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Cardinal_Health
 
Vocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm finalVocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm finalvocera2016ir
 
Alteryx q1'18 investor deck ir
Alteryx q1'18 investor deck   irAlteryx q1'18 investor deck   ir
Alteryx q1'18 investor deck iralteryxinvestor
 
Alteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 finalAlteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 finalalteryxinvestor
 

What's hot (20)

Vocera investordeck august 2018 web version
Vocera investordeck  august 2018 web versionVocera investordeck  august 2018 web version
Vocera investordeck august 2018 web version
 
Investor Presentation
Investor PresentationInvestor Presentation
Investor Presentation
 
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017
 
Med releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 finalMed releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 final
 
Canni med investor presentation third qtr 2017
Canni med investor presentation   third qtr 2017Canni med investor presentation   third qtr 2017
Canni med investor presentation third qtr 2017
 
Hsah spin off merger slides final
Hsah spin off merger slides finalHsah spin off merger slides final
Hsah spin off merger slides final
 
1 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v201 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v20
 
Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817
 
Cats Corporate Presentation_May_2017
Cats Corporate Presentation_May_2017 Cats Corporate Presentation_May_2017
Cats Corporate Presentation_May_2017
 
Verisk investor day 2017
Verisk investor day 2017Verisk investor day 2017
Verisk investor day 2017
 
Investor Presentation - April 2018
Investor Presentation - April 2018Investor Presentation - April 2018
Investor Presentation - April 2018
 
1500090053
15000900531500090053
1500090053
 
1001205097
10012050971001205097
1001205097
 
Akg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressedAkg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressed
 
Verisk investor day 2017
Verisk investor day 2017Verisk investor day 2017
Verisk investor day 2017
 
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
 
Therapix Bioscience
Therapix Bioscience Therapix Bioscience
Therapix Bioscience
 
Vocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm finalVocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm final
 
Alteryx q1'18 investor deck ir
Alteryx q1'18 investor deck   irAlteryx q1'18 investor deck   ir
Alteryx q1'18 investor deck ir
 
Alteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 finalAlteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 final
 

Similar to Investor Presentation

Vocera investordeck may 15 2018 web
Vocera investordeck  may 15 2018 webVocera investordeck  may 15 2018 web
Vocera investordeck may 15 2018 webvocera2016ir
 
Vocera investordeck february 2018 web
Vocera investordeck  february 2018 webVocera investordeck  february 2018 web
Vocera investordeck february 2018 webvocera2016ir
 
Vocera investordeck may 2018 web
Vocera investordeck  may 2018 webVocera investordeck  may 2018 web
Vocera investordeck may 2018 webvocera2016ir
 
Vocera investordeck august 2017 web
Vocera investordeck  august 2017 webVocera investordeck  august 2017 web
Vocera investordeck august 2017 webvocera2016ir
 
Vocera investordeck july august 2017 web
Vocera investordeck  july august 2017 webVocera investordeck  july august 2017 web
Vocera investordeck july august 2017 webvocera2016ir
 
Vocera investordeck september 2017 for web
Vocera investordeck  september 2017 for webVocera investordeck  september 2017 for web
Vocera investordeck september 2017 for webvocera2016ir
 
Vocera investordeck may 12 2017 needham
Vocera investordeck   may 12 2017 needhamVocera investordeck   may 12 2017 needham
Vocera investordeck may 12 2017 needhamvocera2016ir
 
Vocera investordeck march 2018 for web
Vocera investordeck  march 2018 for webVocera investordeck  march 2018 for web
Vocera investordeck march 2018 for webvocera2016ir
 
Vocera investordeck october 2017 for web
Vocera investordeck  october 2017 for webVocera investordeck  october 2017 for web
Vocera investordeck october 2017 for webvocera2016ir
 
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017medreleafinvestor
 
Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017medreleafinvestor
 
Alteryx investor presentation 052017 final
Alteryx investor presentation 052017 finalAlteryx investor presentation 052017 final
Alteryx investor presentation 052017 finalalteryxinvestor
 
Vocera ir master_ february 2019 web
Vocera ir master_ february 2019 webVocera ir master_ february 2019 web
Vocera ir master_ february 2019 webvocera2016ir
 
1001205101
10012051011001205101
1001205101veriskir
 
Vocera investordeck web january 2018
Vocera investordeck  web january 2018Vocera investordeck  web january 2018
Vocera investordeck web january 2018vocera2016ir
 
Vocera investordeck november 2017 web (1)
Vocera investordeck  november 2017 web (1)Vocera investordeck  november 2017 web (1)
Vocera investordeck november 2017 web (1)vocera2016ir
 
Vocera investordeck november 2017 web
Vocera investordeck  november 2017 webVocera investordeck  november 2017 web
Vocera investordeck november 2017 webvocera2016ir
 
Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217alteryxinvestor
 
Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23qrhc
 
IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017ItelGenx
 

Similar to Investor Presentation (20)

Vocera investordeck may 15 2018 web
Vocera investordeck  may 15 2018 webVocera investordeck  may 15 2018 web
Vocera investordeck may 15 2018 web
 
Vocera investordeck february 2018 web
Vocera investordeck  february 2018 webVocera investordeck  february 2018 web
Vocera investordeck february 2018 web
 
Vocera investordeck may 2018 web
Vocera investordeck  may 2018 webVocera investordeck  may 2018 web
Vocera investordeck may 2018 web
 
Vocera investordeck august 2017 web
Vocera investordeck  august 2017 webVocera investordeck  august 2017 web
Vocera investordeck august 2017 web
 
Vocera investordeck july august 2017 web
Vocera investordeck  july august 2017 webVocera investordeck  july august 2017 web
Vocera investordeck july august 2017 web
 
Vocera investordeck september 2017 for web
Vocera investordeck  september 2017 for webVocera investordeck  september 2017 for web
Vocera investordeck september 2017 for web
 
Vocera investordeck may 12 2017 needham
Vocera investordeck   may 12 2017 needhamVocera investordeck   may 12 2017 needham
Vocera investordeck may 12 2017 needham
 
Vocera investordeck march 2018 for web
Vocera investordeck  march 2018 for webVocera investordeck  march 2018 for web
Vocera investordeck march 2018 for web
 
Vocera investordeck october 2017 for web
Vocera investordeck  october 2017 for webVocera investordeck  october 2017 for web
Vocera investordeck october 2017 for web
 
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017
 
Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017
 
Alteryx investor presentation 052017 final
Alteryx investor presentation 052017 finalAlteryx investor presentation 052017 final
Alteryx investor presentation 052017 final
 
Vocera ir master_ february 2019 web
Vocera ir master_ february 2019 webVocera ir master_ february 2019 web
Vocera ir master_ february 2019 web
 
1001205101
10012051011001205101
1001205101
 
Vocera investordeck web january 2018
Vocera investordeck  web january 2018Vocera investordeck  web january 2018
Vocera investordeck web january 2018
 
Vocera investordeck november 2017 web (1)
Vocera investordeck  november 2017 web (1)Vocera investordeck  november 2017 web (1)
Vocera investordeck november 2017 web (1)
 
Vocera investordeck november 2017 web
Vocera investordeck  november 2017 webVocera investordeck  november 2017 web
Vocera investordeck november 2017 web
 
Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217
 
Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23
 
IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017
 

Recently uploaded

Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationWestern Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationPaul West-Sells
 
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024gstubel
 
countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024Kweku Zurek
 
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call GirlsPremium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girlsmeghakumariji156
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Klinik kandungan
 
Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024Philip Rabenok
 
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationThe Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationLeonardo
 
Teekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings ResultsTeekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings ResultsTeekay Corporation
 
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your AreaGorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Areameghakumariji156
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024KDDI
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd
 
Terna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results PresentationTerna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results PresentationTerna SpA
 
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Ltd
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCAMILRI
 
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In DubaiDubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubaikojalkojal131
 
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfCorporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfProbe Gold
 
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样sovco
 

Recently uploaded (20)

Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 ResultsOsisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 Results
 
Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationWestern Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 Presentation
 
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024
 
countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024
 
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call GirlsPremium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
 
SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
 
Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024
 
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdfITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
 
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationThe Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results Presentation
 
Teekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings ResultsTeekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings Results
 
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your AreaGorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
 
Terna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results PresentationTerna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results Presentation
 
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings Presentation
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
 
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In DubaiDubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
 
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfCorporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdf
 
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
 

Investor Presentation

  • 2. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. Safe Harbor and Other Information This presentation contains “forward‐looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. We intend for such forward‐looking statements to be covered by the safe harbor provisions for forward‐looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements include information concerning the market shifting to Vocera, the components of our mission, our accelerating operating leverage and target operating leverage model, and potential future products and services. Forward‐looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates”, “targets,” “guidance,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “prospects,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms, although not all forward‐looking statements contain these identifying words. Forward‐looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. We cannot guarantee that we will achieve the plans, intentions, or expectations disclosed in our forward‐looking statements, and you should not place undue reliance on our forward‐looking statements. Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. We undertake no obligation, and do not intend, to update these forward‐looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current financial quarter. For a more complete discussion of factors that could materially affect our financial results and operations, please refer to our Quarterly Report on Form 10-Q for the period ended March 31, 2018 that we have filed with the SEC, including Part II, Item 1A, “Risk Factors,” and other reports that we file with the SEC. Copies of reports we file with the SEC are posted on our website and are available from us without charge. This presentation shall not constitute an offer to sell or a solicitation of an offer to purchase securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which or to any person to whom such an offer, solicitation or sale would be unlawful. This presentation is strictly confidential and is being made solely in reliance on applicable exemptions from the registration requirements of the Securities Act of 1933. The securities of the Company have not been registered under the Securities Act of 1933 or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and applicable state laws. Any purchaser of such securities will be deemed to have made certain representations and acknowledgments, including, without limitation, that the purchaser is a "qualified institutional buyer" as defined in Rule 144A under the Securities Act of 1933. Statement Regarding Use of Non-GAAP Financial Measures This presentation contains certain non-GAAP financial measures. For a presentation of the most directly comparable financial measures calculated in accordance with GAAP, and a reconciliation of these non-GAAP measures to the GAAP measures, please see the appendix. The non-GAAP financial measures we present are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. We encourage investors to carefully review our results of operations under GAAP in addition to the non-GAAP information we present to more fully understand our business. 2 Forward-Looking Statements
  • 3. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 3 • Large market shifting toward Vocera • Market leader with compelling ROI • Large wins validate sales strategy • Software acquisition extends platform • Accelerating operating leverage Our Opportunity * The Company adopted ASC 606 effective January 1, 2018. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the adoption of ASC 606 revenue in 2016 and 2017 was $127.7MM and $162.5MM, respectively; and A-EBITDA was 3% and 8% of revenue in 2016 and 2017, respectively. The adoption of ASC 606 did not impact 2014 or 2015. Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and option liabilities. See Appendix for a reconciliation. Guidance was provided April 26, 2018. YoY Rev. Growth $95 $104 $132 $166 $183* -13% -3% 8% 10% 11% FY14 FY15 FY16 FY 17 FY18* Guide High-End Revenue A-EBITDA % (7%) 9% 27% 26% 10%
  • 4. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. Vocera Before Vocera Now Communications Badge-Centric Point Product Department Sale Clinical Workflow Software-Centric Complete Solution Enterprise Sale Strategic Transformation 4
  • 5. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. Quality ResiliencyPatient-CenteredCost Enhance how care is provided to help patients to achieve better outcomes Increase operational efficiencies Improve patient experience by allowing caregivers to be Patient Centered Improve the caregiver experience by improving workflow and empowering care teams The Quadruple Aim 5 Our Mission
  • 6. ©2017 Vocera Communications. All rights reserved. 6 Broadcast to OR Turnover Call on-call Orthopedic Surgeon Secure text to on-call Cardiologist Urgent call to ED Charge Nurse The Call Sheet Transformed
  • 7. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 7 Communicate, Collaborate, Make Informed Decisions Quickly PHYSICIAN ✓ Collaborate whether inside or outside the hospital NURSE ✓Reach the right person without names or numbers NURSE SUPERVISOR ✓Keep nurses and patients safer HOSPITALIST ✓Receive timely, relevant patient information HOUSEKEEPING ✓Increase bed turnover Alert & Alarm Intelligence Electronic Health Record Nurse Call Physiologic Monitor Bed Management Real-Time Location System Laboratory Info System INPUTS Dynamic Data Aggregation of Patient Events and Context OUTPUTS Context-Aware Events Response and Critical Collaboration Dynamic Master Directory
  • 8. ©2017 Vocera Communications. All rights reserved. 6,986 Hospitals in the U.S.(1) U.S. Hospitals 1118 (1) 8 Large Global Market Opportunity (1 ) Based on Definitive US Healthcare Database. As of December 31, 2017 International Healthcare Facilities ~250 Global Non- Healthcare Facilities ~270 ~$6 Billion Global Market Opportunity 1118 5220 Vocera Hospitals US Hospitals 18% U.S. Penetration Rate (1) (6338 Total US Hospitals) *Federal numbers are for acute care hospitals, do not include clinics or ambulatory care centers ~130 new healthcare facilities in 2017 Fed Hospitals (1) Vocera* Total (1) VA 73 164 DoD 21 46 Total 94 210 U.S. Healthcare (non hospital) 100
  • 9. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 9 Recent Platform Wins Validate Strategy MEDCOM
  • 10. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 10 The Patient Journey in a Real Time Health System Admission, discharge, transfer Test results Nurse- physician consult Obtain, clarify, change orders Update Patient status Streamline Patient flow “The RTHS uses information and communication technology to reduce the time in which patient information and medical knowledge is collected, analyzed, shared and applied.” Source: Gartner Real-Time Health System Technologies, July 2017 Requirements: • Aware • Integrated • Collaborative • Patient-Centric
  • 11. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. (1) Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and option liabilities. See appendix for a reconciliation. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the company’s adoption of ASC 606 revenue was $127.7 MM and $162.5MM in 2016 and 2017, respectively; and adjusted EBITDA was $4.3MM and $13.1MM in 2016 and 2017, respectively. Revenue (1) Financial Highlights Adjusted EBITDA $36.6 $40.2 $132.0 $166.0 Q117 Q118 2016 2017 ($inMillions) -$0.6 $1.8 $10.1 $16.4 Q117 Q118 2016 2017 ($inMillions) Q1 2018 Results exceeded expectations • Q1: 10% Revenue Growth, 2017: +26% • Q1: 41% Software Growth, 2017: +26% • $109.2 million Backlog + Deferred Revenue Solid Customer Base and Value Proposition • 95%+ s/w maintenance renewal rate • Strong competitive win rate Expanding Profitability and Cash Flow • A-EBITDA $16.4 million in 2017 (1) • A-EBITDA $1.8 million in Q118 • $82 million in cash on balance sheet 11 +10% +26% Financial Highlights N/MMargin (%) 4.5% 7.7% 9.9%
  • 12. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 12 % 2017 Revenue 17% Software Maintenance *All recurring 32% Professional Services *15%+ recurring 13% 38% Devices *44% recurring Diversified Revenue, High Visibility • Greater than 50% of revenues are recurring • High visibility • Low customer concentration Software *10%+ subscription *%’s are of the specific category, not company revenue.
  • 13. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. Software Maintenance Professional Services Software Hardware 13 Larger Deals, Higher Software Mix $9.4M $14.9M $14.4M $3.5M $3.1M $ values are in bookings VA = New facilities added in 2017 $1.9M 31% 18% 32% 30% 13% 34% 12% 14% 13% 19% 24% 15% 39% 29% 35% 19% 56% 51% 18% 39% 20% 32% 7%
  • 14. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 14 Actual 2014 2015 2016 2017 R&D % of Revenue 17% 15% 13% 15% S&M % of Revenue 47% 41% 35% 31% G&A % of Revenue 13% 12% 11% 10% Target Model 12% 29% 8% Sales Notes • All numbers are non-GAAP, see appendix for reconciliation. • Mean peer group enterprise value comps are 3-4x Revenue and 12-15x A-EBITDA. • 2016 and 2017 reflect the company’s adoption of ASC 606. Prior to the Company’s adoption of ASC 606 the corresponding percentages would have been as follows. For 2016: 63%, 13%, 37%, 11%, 61% and 3% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively. For 2017: 64%, 16%, 32%, 10%, 58%, and 8% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively. Drivers Operating Leverage Drives Significant Value
  • 17. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 17 GAAP to Non-GAAP Reconciliations of Net Income to Adjusted EBITDA 2014-2017 As Adjusted As Reported Change As Adjusted As Reported Change GAAP net income (loss) (10,897) (14,217) 3,320 (11,400) (17,267) 5,867 Add back: Stock compensation expense 18,196 18,196 - 12,035 12,035 - Acquisition related expenses 1,269 1,269 - 5,822 5,822 - Interest income (549) (549) - (627) (627) - Depreciation and amortization expense 7,643 7,643 - 3,770 3,770 - Provision for income taxes 759 759 - 529 529 - Non-GAAP adjusted EBITDA 16,421 13,101 3,320 10,129 4,262 5,867 As Adjusted: financials recast in accordance with the Company's adoption of ASC 606. As Reported: financials as initially reported and does not include adjustments related to the adoption of ASC 606. Year EndedDecember 31, 2017 Year EndedDecember 31, 2016 2015 2014 GAAP net loss (17,106)$ (28,297)$ Add back: Stock compensation expense 11,005 11,084 Acquisition expense - 899 Litigation expense 9 630 Restructuring expense - 654 Interest income (446) (267) Depreciation and amortization expense 3,271 3,000 Provision for income taxes 473 324 Non-GAAP adjusted EBITDA (2,794)$ (11,973)$ Twelve months endedDecember 31,
  • 18. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 18 GAAP to Non-GAAP Reconciliations of Net Income to Adjusted EBITDA Q1’18 and Q1’17
  • 19. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 19 GAAP to Non-GAAP GM & Opex Reconciliation 2017 & 2016 under ASC 606
  • 20. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 20 GAAP to Non-GAAP GM & Opex Reconciliation 2017 & 2016 under ASC 605
  • 21. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 21 GAAP to Non-GAAP Reconciliation 2015 Year ended December 31, 2015 Stock Intangible (In thousands) GAAP compensation amortization Litigation Total Non-GAAP 2015 expense (a) (b) expense (c) adjustments 2015 Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited) Revenue Product $ 55,716 $ — $ 55,716 Service 48,370 — 48,370 Total revenue 104,086 — — — — 104,086 Cost of revenue Product 19,666 232 323 555 19,111 Service 19,844 1,036 — 1,036 18,808 Total cost of revenue 39,510 1,268 323 — 1,591 37,919 Gross profit 64,576 (1,268) (323) — (1,591) 66,167 Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) Research and development 16,990 1,072 — 1,072 15,918 Sales and marketing 47,647 4,486 229 4,715 42,932 General and administrative 16,734 4,179 243 9 4,431 12,303 Total operating expenses 81,371 9,737 472 9 10,218 71,153 (a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense. (b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense. (c) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit.
  • 22. ©2017 Vocera Communications. All rights reserved.©2017 Vocera Communications. All rights reserved. 22 GAAP to Non-GAAP GM & Opex Reconciliation 2014 Year ended December 31, 2014 (In thousands) Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited) Revenue Product 51,095$ $ - 51,095$ Services 44,326 - 44,326 Total Revenue 95,421 - - - - - - 95,421 Cost of Revenue Product 18,766 254 429 72 755 18,011 Services 18,470 924 26 950 17,520 Total cost of revenue 37,236 1,178 429 - - 98 1,705 35,531 Gross profit 58,185 (1,178) (429) - - (98) (1,705) 59,890 Research and development 18,089 1,056 11 54 1,121 16,968 Sales and marketing 49,694 4,111 291 83 4,485 45,209 General and administrative 18,481 4,739 93 888 630 419 6,769 11,712 Total operating expenses 86,264 9,906 384 899 630 556 12,375 73,889 (a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense. (b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense. (c) This operating expense adjustment reflects the accounting impact of acquisitions, including for Q4 2014 $800K of consideration deemed to be compensation. (d) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit. (e) This operating expense adjustment reflects impact of restructuring expense. Non-GAAP 2014 Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) GAAP 2014 Stock compensation expense (a) Intangible amortization (b) Acquisiton expense (c) Litigation expense (d) Restructuring expense (e) Total Adjustments